Barriers GLP-1 adherence systems face include cost, side effects, and care models; health systems use structured ...

Employers GLP-1 coverage dilemma grows as health systems like Jefferson Health cut costs with lifestyle programs for 65,000 employees.

Mounting research suggests GLP-1 drugs, which are used to treat diabetes and obesity, may one day help people with alcohol ...

The National Academies’ Forum on Neuroscience and Nervous Systems Disorders hosted a workshop on September 10, 2024, they brought together diverse perspectives to examine the promising but ...

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, ...